EUVIMEDOpdag EUVIMED
Open access

Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study

Han Chen, Xinyu Tang, Wei Su, Shuo Li, Ruoyun Yang, Hong Cheng, Guoxin Zhang, Xiaoying Zhou

Aging · 2023

DOI: 10.18632/aging.205347 ↗

At a glance

Journal article in Aging, 2023. Written by Han Chen and 7 co-authors. Institution: Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China. Major MEDLINE topics: Diabetes Mellitus, Type 2, Neoplasms. Cited 6 times so far (Crossref); 34 references. The full text is freely available in PubMed Central.

AbstractSubjectsBibliografiske oplysningerCiteRelated studies

Abstract (original language)

BACKGROUND: Despite the widespread use of statins, newer lipid-lowering drugs have been emerging. It remains unclear how the long-term use of novel lipid-lowering drugs affects the occurrence of cancers and age-related diseases. METHODS: A drug-target Mendelian randomization study was performed. Genetic variants of nine lipid-lowering drug-target genes (HMGCR, PCKS9, NPC1L1, LDLR, APOB, CETP, LPL, APOC3, and ANGPTL3) were extracted as exposures from the summary data of Global Lipids Genetics Consortium Genome-Wide Association Studies (GWAS). GWAS summary data of cancers and noncancerous diseases were used as outcomes. The inverse-variance weighted method was applied as the main statistical approach. Sensitivity tests were conducted to evaluate the robustness, pleiotropy, and heterogeneity of the results. RESULTS: In addition to marked effects on decreased risks of atherosclerotic cardiovascular diseases, genetically proxied lipid-lowering variants of PCKS9, CETP, LPL, LDLR, and APOC3 were associated with longer human lifespans (q

Subjects

MeSH terms (MEDLINE)

Diabetes Mellitus, Type 2NeoplasmsHumansGenome-Wide Association StudyMendelian Randomization AnalysisCholesterol, LDLHypolipidemic AgentsAgingApolipoproteins BPolymorphism, Single NucleotideAngiopoietin-Like Protein 3

Author keywords

Mendelian randomizationaginglipid-lowering drugs

Substances

Cholesterol, LDLHypolipidemic AgentsApolipoproteins BANGPTL3 protein, humanAngiopoietin-Like Protein 3

Authors and institutions

  • Department of Gastroenterology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
  • Department of Radiation Oncology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.
  • Department of Neurology, The First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China.

Cite

APA

Chen, H., Tang, X., Su, W., Li, S., Yang, R., Cheng, H., Zhang, G., & Zhou, X. (2023). Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study. Aging. https://doi.org/10.18632/aging.205347

Vancouver

Chen H, Tang X, Su W, Li S, Yang R, Cheng H, et al. Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study. Aging. 2023. doi:10.18632/aging.205347

BibTeX
@article{Chen2023,
  author = {Chen, Han and Tang, Xinyu and Su, Wei and Li, Shuo and Yang, Ruoyun and Cheng, Hong and Zhang, Guoxin and Zhou, Xiaoying},
  title = {Causal effects of lipid-lowering therapies on aging-related outcomes and risk of cancers: a drug-target Mendelian randomization study},
  journal = {Aging},
  year = {2023},
  doi = {10.18632/aging.205347}
}
Start for free →